Literature DB >> 18671474

Update on tizanidine for muscle spasticity and emerging indications.

Gerard Malanga1, Raymond D Reiter, Edward Garay.   

Abstract

BACKGROUND: Tizanidine hydrochloride, an alpha(2)-adrenergic receptor agonist, is a widely used medication for the treatment of muscle spasticity. Clinical studies have supported its use in the management of spasticity caused by multiple sclerosis (MS), acquired brain injury or spinal cord injury. It has also been shown to be clinically effective in the management of pain syndromes, such as: myofascial pain, lower back pain and trigeminal neuralgia. This review summarizes the recent findings on the clinical application of tizanidine.
OBJECTIVE: Our objective was to review and summarize the medical literature regarding the evidence for the usefulness of tizanidine in the management of spasticity and in pain syndromes such as myofascial pain.
METHODS: We reviewed the current medical and pharmacology literature through various internet literature searches. This information was then synthesized and presented in paragraph and table form. RESULTS/
CONCLUSION: Tizanidine hydrochloride is a very useful medication in patients suffering from spasticity caused by MS, acquired brain injury or spinal cord injury. It can also be helpful in patients suffering from chronic neck and/or lower back pain who have a myofascial component to their pain. Doses should be started at low dose and gradually titrated to effect.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18671474     DOI: 10.1517/14656566.9.12.2209

Source DB:  PubMed          Journal:  Expert Opin Pharmacother        ISSN: 1465-6566            Impact factor:   3.889


  14 in total

Review 1.  G protein-coupled receptors as therapeutic targets for multiple sclerosis.

Authors:  Changsheng Du; Xin Xie
Journal:  Cell Res       Date:  2012-06-05       Impact factor: 25.617

Review 2.  Comprehensive review of cardiovascular toxicity of drugs and related agents.

Authors:  Přemysl Mladěnka; Lenka Applová; Jiří Patočka; Vera Marisa Costa; Fernando Remiao; Jana Pourová; Aleš Mladěnka; Jana Karlíčková; Luděk Jahodář; Marie Vopršalová; Kurt J Varner; Martin Štěrba
Journal:  Med Res Rev       Date:  2018-01-05       Impact factor: 12.944

Review 3.  Combination therapy for neuropathic pain: a review of current evidence.

Authors:  Yakov Vorobeychik; Vitaly Gordin; Jianren Mao; Lucy Chen
Journal:  CNS Drugs       Date:  2011-12-01       Impact factor: 5.749

Review 4.  Update on neuropathic pain treatment: ion channel blockers and gabapentinoids.

Authors:  Lucy Chen; Jianren Mao
Journal:  Curr Pain Headache Rep       Date:  2013-09

5.  In Support of Initial Parenteral Medical Management of Intrathecal Baclofen Withdrawal in Spasticity Patients.

Authors:  Brian L LaRowe; Vicki M Nussbaum
Journal:  J Pharm Technol       Date:  2021-08-12

Review 6.  Translational pain research: achievements and challenges.

Authors:  Jianren Mao
Journal:  J Pain       Date:  2009-07-22       Impact factor: 5.820

Review 7.  Safety and efficacy of incobotulinumtoxinA as a potential treatment for poststroke spasticity.

Authors:  Andrea Santamato
Journal:  Neuropsychiatr Dis Treat       Date:  2016-01-27       Impact factor: 2.570

8.  Management of Tizanidine Withdrawal Syndrome: A Case Report.

Authors:  A Suárez-Lledó; A Padullés; T Lozano; S Cobo-Sacristán; M Colls; R Jódar
Journal:  Clin Med Insights Case Rep       Date:  2018-02-13

9.  Combination of conditional random field with a rule based method in the extraction of PICO elements.

Authors:  Samir Chabou; Michal Iglewski
Journal:  BMC Med Inform Decis Mak       Date:  2018-12-04       Impact factor: 2.796

10.  Treatment of nocturnal leg cramps by blockade of the medial branch of the deep peroneal nerve after lumbar spine surgery.

Authors:  Takayuki Imura; Gen Inoue; Toshiyuki Nakazawa; Masayuki Miyagi; Wataru Saito; Kentaro Uchida; Takanori Namba; Eiki Shirasawa; Naonobu Takahira; Masashi Takaso
Journal:  Brain Behav       Date:  2015-08-07       Impact factor: 2.708

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.